When employing HER2-directed antibodies or tyrosine kinase inhibitors in cancer treatment, either in combination with chemotherapy or as single agents, therapeutic resistance typically occurs within months of starting therapy (see [19] for review). The gene discussed is ERBB2; the disease is cancer.